Epizyme scores important follicular lymphoma approval with TazverikEpizyme has scored an important FDA win after the regulator approved its Tazverik (tazemetostat) in follicular lymphoma. Tazverik is already approved in Share XEpizyme scores important follicular lymphoma approval with Tazverikhttps://pharmaphorum.com/news/epizyme-unlocks-more-sales-with-tazverik-follicular-lymphoma-approval/